Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy

To describe the efficacy of tocilizumab in patients with Graves' orbitopathy resistant or dependent to steroids and compare to rituximab treated patients. Graves's orbitopathy response was considered as decrease of at least 2 points of the CAS. Twenty-one patients were included, 7 patients...

Full description

Saved in:

Bibliographic Details
Published in:	Ocular immunology and inflammation Vol. 30; no. 2; pp. 500 - 505
Main Authors:	Bennedjaï, Amin, Bouheraoua, Nacim, Gatfossé, Marc, Dupasquier-Fediaevsky, Laurence, Errera, Marie-Hélène, Tazartes, Michel, Borderie, Vincent, Hennocq, Quentin, Dellal, Azeddine, Riviere, Sebastien, Heron, Emmanuel, Fain, Olivier, Mekinian, Arsène
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis 17-02-2022
Subjects:	Antibodies, Monoclonal, Humanized Graves Ophthalmopathy - drug therapy Graves's orbitopathy Humans Immunologic Factors - therapeutic use outcome rituximab Rituximab - therapeutic use Steroids Tocilizumab Tocilizumab outcome rituximab Graves’s orbitopathy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To describe the efficacy of tocilizumab in patients with Graves' orbitopathy resistant or dependent to steroids and compare to rituximab treated patients. Graves's orbitopathy response was considered as decrease of at least 2 points of the CAS. Twenty-one patients were included, 7 patients were treated with tocilizumab and 14 with rituximab. The primary was achieved in all 7 patients (100%) on tocilizumab and 9 out of 14 patients on (64%) rituximab (p = .17). Mean change in CAS was consistent with a decrease of 3.3 ± 0.5 points in patients on tocilizumab versus 2.5 ± 1.9 in patients on rituximab (p = .07). One patient on tocilizumab (14%) and 4 patients (29%) on rituximab experienced significant relapse during the follow-up. The difference in relapse-free survival was not significant in patients on tocilizumab (10.8 ± 4 months) compared with rituximab (17.88 ± 3.66). We showed a significant improvement in the CAS, visual acuity, diplopia, and proptosis with both tocilizumab and rituximab.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0927-3948 1744-5078
DOI:	10.1080/09273948.2020.1808688